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Abstract
Background: Universal newborn screening for early detection of children affected by sickle cell
disorders and cystic fibrosis is currently being implemented across England. Parents of infants
identified as carriers of these disorders must also be informed of their baby's result. However there
is a lack of evidence for most effective practice internationally when doing so. This study describes
current or proposed models for imparting this information in practice and explores associated
challenges for policy.
Methods: Thematic analysis of semi-structured interviews with Child Health Coordinators from
all English Health Regions.
Results: Diverse methods for imparting carrier results, both within and between regions, and
within and between conditions, were being implemented or planned. Models ranged from result by
letter to in-person communication during a home visit. Non-specialists were considered the best
placed professionals to give results and a similar approach for both conditions was emphasised.
While national guidance has influenced choice of models, other factors contributed such as existing
service structures and lack of funding. Challenges included uncertainty about guidance specifying
face to face notification; how best to balance allaying parental anxiety by using familiar non-specialist
health professionals with concerns about practitioner competence; and extent of information
parents should be given. Inadequate consideration of resource and service workload was seen as
the main policy obstacle. Clarification of existing guidance; more specific protocols to ensure
consistent countrywide practice; integration of the two programmes; and 'normalising' carrier
status were suggested as improvements.
Conclusion: Differing models for communicating carrier results raise concerns about equity and
clinical governance. However, this variation provides opportunity for evaluation. Timely and more
detailed guidance on protocols with clarification of existing recommendations is needed.
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Background
Part of the newborn bloodspot programme [1], universal
newborn screening for sickle cell disorders (SCD) is now
fully implemented across England [2] and will be for
cystic fibrosis (CF) [3] by mid-2007. In addition, a linked
antenatal haemoglobin disorder (HD) screening pro-
gramme is being rolled out; universal in areas with a high
prevalence and selective in low prevalence areas. High
prevalence areas are those where sickle cell disease is esti-
mated to affect more than 1.5 per 10,000 pregnancies and
low prevalence those with less than 1.5 per 10,000. New-
born screening aims to identify babies affected by these
conditions; however screening also identify infants who
are carriers. While concerns have been raised about iden-
tifying carriers of genetic conditions by population screen-
ing and how to (even whether to) communicate results [4-
7], English policy is that parents have to be informed.
Despite decades of universal newborn screening for SCD
in the USA, and more recently for CF, there is no clearly
established model for effective communication of carrier
status internationally [8].
Both SCD and CF are recessively-inherited disorders and
carriers are healthy. Newborn screening for SCD identifies
all carriers of structural haemoglobin variants (screening
identifies carriers of 'unusual haemoglobins' of which the
most common is Sickle Cell; for ease of reference, SCD is
used in this paper when referring to all unusual haemo-
globins detected by screening) but not thalassaemia carri-
ers and there is no available method of testing without
detecting carriers. The national protocol for CF screening
in England aims to identify a maximum number of chil-
dren with CF whilst minimising the number of carriers.
The protocol involves an initial immuno-reactive
trypsinogen (IRT) measurement which identifies babies at
high risk for CF. These samples are further tested by a two-
stage DNA screen for a small panel of CF mutations. Those
with two mutations will have CF. For those with only one
mutation or no mutation detected but with a very high
initial IRT, a second blood sample will be requested and a
further IRT measurement performed at 21–28 days when
it is more discriminatory. While an elevated IRT itself does
not select in favour of carrier status, most of these babies
will be carriers defined by limited DNA testing. However,
because not all mutations are identified, a small propor-
tion of those defined as carriers may actually have two CF
variants and have the condition (because they have inher-
ited two CF variants, one identified by IRT and one not
identified).
With a SCD incidence of 1:2400 affected babies per year
in the UK, the NHS Sickle Cell and Thalassaemia Screen-
ing Programme estimate that about 8000 newborn carri-
ers were detected in 2006 from about 550,000 babies
screened [9]. Cystic fibrosis has a slightly lower incidence
(1:2500 affected babies per year born in the UK) with
approximately 1 in 25 of the population estimated to be a
carrier of which only a small proportion will be identified
by newborn screening [3]. In England annually about 240
babies with CF are born [10] and current screening proto-
cols are expected to identify an equivalent or slightly
higher number of carriers. Thus, compared to CF, num-
bers of newborn SCD carriers detected are considerable.
For example at a regional level, during a 12-month period
573 SCD carriers and 16 CF carriers were detected in a
population with an annual birth rate of 70,000 [11].
Prior to national programmes, newborn screening was
mostly offered on an ad hoc basis, with universal CF
screening available to 20% of babies (areas served by lab-
oratories in East Anglia, East Midlands, South Yorkshire
and Leeds) for over 15 years and over 10 years for SCD in
some areas in London, East of England and Birmingham.
Over this period, although practice for informing parents
of their infants' carrier status has varied according to con-
dition and locality [12], the need for clear protocols for
communicating carrier information is recognised [13]. In
England, thus far, guidance issued by the UK Newborn
Screening Programme Centre recommends that carrier
results should be given to parents 'as soon as possible; by
a well-informed health professional; in person, or by
phone, and followed up in person as soon as possible;
and supported by written information' [10]. This guid-
ance does not distinguish between CF and SCD carrier sta-
tus. However there are no data on models being used,
extent of variation, and experience of implementation fol-
lowing the advent of universal screening across England.
This paper reports findings from a descriptive study, part
of a larger study funded by the Health Technology Assess-
ment programme [14] also exploring parents' and health
professionals' experience, on models for giving newborn
carrier results and emerging policy in this context.
Methods
Semi-structured telephone interviews were conducted (by
HP) with the Regional Child Health Co-ordinator from
each of the nine English health regions during the second
half of 2006. Consent to be interviewed was initially
obtained by email and again verbally on tape at the start
of the interview.
Participants were invited to reflect on the extent of
regional implementation of CF and SCD newborn screen-
ing, actual or proposed models for giving results, the need
for condition specific models, who should give the results,
and suggestions for improving current practice and policy.
Respondents were also able to raise other issues of impor-
tance relevant to the subject. Where informants were una-
ble to provide sufficient details, brief telephone calls orBMC Health Services Research 2007, 7:203 http://www.biomedcentral.com/1472-6963/7/203
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emails to specialist services were used to acquire supple-
mentary information. Interviews were tape-recorded and
transcribed verbatim. Data were thematically coded and
analysed according to emergent themes. Interviewees
were invited to give feedback on a draft version of this
paper prior to submission for publication.
The study was approved by the West Midlands Research
Ethics Committee.
Results
Description of regional models
Participants reported a variety of models, proposed or
already operational, for imparting carrier results (see table
1 for summary of practice across England). Of note is
diversity of models both within and between regions and
both within and between conditions. Only one region is
implementing the same model for both conditions. All
regions are informing parents of CF carriers in person
compared to a range of methods, from notification by let-
ter alone to personal contact, for SCD carriers. Health Vis-
itors (HVs) have a prominent role, including family's
usual HV and those specially trained to communicate car-
rier results.
Factors shaping choice of method
National guidance
National guidance (as issued by the UK Newborn Screen-
ing Programme Centre [10]) for implementation most
commonly influenced choices of methods for communi-
cating carrier results. The perception was that guidance
was more specific for the CF compared to the SCD pro-
gramme. However, experience of implementing SCD
screening first has informed thinking about CF.
'... because there were lines being drawn in the sand as to
who should actually do this information, who should actu-
ally give this information and obviously we knew that Cystic
Fibrosis was coming...so I adopted the model for the Sickle
screening programme as well.' (CHC 04)
Resource constraints
Inadequate funding has affected implementation of both
the delivery of screening and in particular the choice of
methods for communicating carrier results. This has
necessitated efforts to secure funding from local sources;
often short term and dependent on an individual man-
ager's resourcefulness or sway within the local health sys-
tem. Where no additional funds could be realised, existing
staff have had to take on communication of results in
addition to their usual workload. Inevitably, these finan-
cial constraints have, in some regions, led to compromise
and 'quick fix' models for communicating carrier results.
'...I don't think there was due consideration given to the
workload associated with giving carrier results and I think
that was an oversight. There doesn't seem to have been any
thoughts on how it would be... It needs to be properly
Table 1: Proposed English Regional methods for imparting newborn carrier results
Region SCD carriers Sceening 
started in
CF carriers Screening 
started in
North West In person by purpose trained health visitor 2005 In person by purpose 
trained health visitor




In person by Haemoglobinopathy counsellor
OR
Letter with result plus appointment for counselling
2004 In person specialist 
counsellor plus family 
health visitor
Not yet started at 
time of interview
South West In person by family health visitor or Haemoglobinopathy counsellor
OR
Letter with result plus option to attend Haemoglobinopathy service
2004 – 2006 In person by genetic 
counsellor or antenatal 
screening co-ordinator
Not yet started at 
time of interview
London In person by family health visitor or Haemoglobinopathy counsellor
OR
Letter with result plus appointment for counselling, or option to 
attend specialist service, or 'drop-in' clinic
1995 – 2005 Undecided at the time of 
data collection
Not yet started at 
time of interview
North East In person by Haemoglobinopathy counsellor plus family health 
visitor
2005 In person by purpose 
trained health visitor plus 
family health visitor




In person by Haemoglobinopathy counsellor or purpose trained 
health visitor
OR
Letter with result plus appointment for counselling




South Eastern Haemoglobinopathy counsellors contact and inform parents (details 
on exact methods not collected)
2003 – 2006 In person by purpose 
trained midwife
2006 in Thames 
Valley
East Midlands In person by General Practitioner plus referral to clinical genetics 
or follow-up by Haemoglobinopathy counsellor





In person by purpose trained health visitor or Haemoglobinopathy 
counsellor
OR
Letter with result plus appointment for counselling
2004 In person by family health 
visitor plus specialist CF 




Yorkshire)BMC Health Services Research 2007, 7:203 http://www.biomedcentral.com/1472-6963/7/203
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accounted for, like we introduce services and they give 4
quid a baby for the lab but it affects every different compo-
nent part of the service. It affects the midwives and their
counselling, it affects the health visitors giving the results
and it affects the child health record departments who have
to adapt their systems of working to record the results.'
(CHC 02)
'... it's [informing carriers]all done on goodwill, the PCTs
are asking where's the funding for this? And obviously it
does take up some time, some practitioners' time.' (CHC
04)
Low or high prevalence areas for Haemoglobin Disorders
Specialist services have been operational in high preva-
lence HD areas long before the introduction of universal
newborn screening. Bringing distinct advantages, such as
expertise and referral protocols, a consequence is that
regional plans for models of carrier results have to incor-
porate existing practice and organisational structures,
resulting in less scope for innovation in some areas.
Requesting changes to existing practice was a challenge,
leading some interviewees to prefer starting service plan-
ning from scratch.
'...it was easier to do the area that was a blank sheet because
then you could do how best fitted what the geography and,
you know, where the funds and all those sorts of things
available were and you've also got some handle on what
they do and can say what they should or shouldn't do.
Whereas when there's already something in place it's
harder isn't it?' (CHC 08)
In contrast, there were concerns about reporting results in
low prevalence HD areas due to lack of resources and
practitioner knowledge. Thus, although low prevalence
settings provided opportunities for trying out new models
of result giving, in some areas urgency of need necessi-
tated rapid implementation before localities were suffi-
ciently prepared to deliver results.
'Our real problem has been our low prevalence areas...it
was little bit hit and miss to be quite honest. We had a
case... where we found 60 children hadn't been given
results. And that was a bit...because people didn't know
quite what to do with it, how to do it...' (CHC 05)
Local consultation and preferences
Regional implementation groups were a common mecha-
nism for discussion and planning of proposed models.
For some, the challenge was to find a fit between national
guidance and local resources and preferences. Regions
who consulted widely about this specific issue and
ensured extensive health professional (e.g. Directors of
Public Health, Primary Care Trust screening leads, paedi-
atricians, heads of midwifery and health visiting, etc)
engagement found that the process benefited implemen-
tation of the screening programme as a whole.
'I think without doubt the implementation has brought
more people around the table...and trying to ensure that
there is linkage and involvement across the whole of the
screening profession. So making sure that every professional
group, primary, tertiary and secondary level specialists have
been involved in that decision making has been beneficial.'
(CHC 07)
A role for non-specialists
With some exceptions, most interviewees expressed a
strong preference that conveying carrier results should be
a task undertaken by non-specialist health professionals.
During interviews respondents used the term 'specialists'
when referring to genetic counsellors, Haemoglobinopa-
thy counsellors and Cystic Fibrosis nurses and regarded all
other health professionals involved in communicating
carrier status information as 'non-specialists'. Key to this
position was the view that carriers were healthy. Utilising
a specialist practitioner in this role could cause parents to
believe that their baby was ill and increase their anxiety.
Specialist time was more appropriate for providing further
information to families who wanted to know more or
wanted to discuss future reproductive decisions. While
support for non-specialists giving results was consistent,
informants were uncertain about how best to balance
allaying parental anxiety by using a non-specialist and
concerns about practitioner competence.
'And we would like for them [specialist HD counsellors]
to spend more time doing the specialist stuff that a health
visitor couldn't possibly do... for the carriers it's quite a
large workload and yet it doesn't need super-specialist peo-
ple, it needs somebody with some extra training and some
expertise and it's sort of half-way house.' (CHC 06)
Respondents working in regions where specialists were
currently involved in giving results did not see this as a
problem, though they were not insistent that specialists
should be involved. In one region concern had arisen
about non-specialists giving CF carrier results because of
the small risk that some carriers may be affected.
The importance of involving the family's usual HV in giv-
ing results was highlighted as the best way to minimise
parental anxiety; either as the sole professional giving the
results, or visiting the family together with a specialist or
purpose trained non-specialist. Ensuring appropriate
training for HVs was an important consideration.
Whether to train all to give results, knowing that some
may never come across a carrier case, or to concentrate
training to a selected group who would take on this roleBMC Health Services Research 2007, 7:203 http://www.biomedcentral.com/1472-6963/7/203
Page 5 of 8
(page number not for citation purposes)
and accompany the family HV remained an ongoing
debate for some regions.
'...it seems to me that the best person to give the results so
that it isn't worrying is in the middle of a routine health vis-
itor visit without the phone call to say, ' hey can I see you',
especially because in a sense that's making anxieties. But
how do we maintain competence if even at local level you
know no health visitor is going to be doing it every week say
or even once a month so I think there's actually a real
dilemma... ' (CHC 06)
Condition specific or same approach for both conditions
None of the interviewees were in favour of separate mod-
els for the two conditions. Two respondents, who had not
yet implemented CF newborn screening, wanted to await
further experience while others expressed strong prefer-
ence for similar models and for close working between the
two screening programmes. Another suggested that the
difference between carrier results for the two conditions
was over stated.
'...I think there should be [the same model] ...I've thought
about this quite a lot because with cystic fibrosis the results
can be difficult to interpret and some of the mutations the
significance of those isn't known. But then I thought with
sickle cell screening some of the haemoglobin variants, the
significance of those is unclear so the results of that can be
equally as difficult to interpret and not always straightfor-
ward'. (CHC 01)
A common view was that there were more similarities,
such as carrier status, recessive inheritance, and skills
required to inform parents, than differences between the
conditions. Therefore, it appeared logical to have the same
protocol and organisational structure, albeit with some
variation, for giving results.
'Well when we were putting the whole system [SCD new-
born screening]into place in the back of our mind all the
time was the fact that CF has got to roll out and it makes
sense to use the same mechanism because the counselling
skill is the same isn't it? You know, telling somebody that
there's a problem with their baby and this is the genetics
and you know, that sort of skill...a counselling skill is a
counselling skill really isn't it?' (CHC 08)
'I would think it should be the same method, you know, I
think it should be. Ideally I mean it's the same recessive
condition that you're describing, the same genetics involved
so you know I'd be of the opinion you could do both.' (CHC
03)
Parity in methods for the two conditions was also seen as
a way of addressing longstanding inequity in NHS service
provision for HD compared to CF.
'I think it [methods for giving carrier results]should be
standard but...because I do find it...I do find it personally
irritating that there's this difference between sickle cell and
CF. And professionally I think, well sickle cell is a genetic
condition so why don't clinical genetics see it as their remit
a little bit more because it is an inherited condition... but
that's always been the way. Sickle cell services seem to have
existed running parallel to clinical genetics and erm...so as
I say, it's [Haemoglobinopathy Disorders]probably a bit
of Cinderella area...' (CHC 01)
Suggestions for advancing practice and policy
The need to clarify what was meant in the guidance by
'communicating in person' was a priority. Personal
informing was seen as a costly process and some respond-
ents suggested that an appropriate leaflet with contact
details for further information could be as effective as a
personal visit. Others considered using only written infor-
mation unsatisfactory as varying reading levels would
increase misunderstanding and service providers would
not know that parents had received the information.
'...I think we need a better definition of what is 'communi-
cated in person' because you could interpret that, couldn't
you, as here's the leaflet read it, it could be here's the leaflet
shall we go through it together...erm...through the whole
thing about you know a specialist ringing up and saying
nothing to worry about but I need to see you...erm... The
other thing is in the 'in person', I mean if you've got a fam-
ily that don't speak English...if the health visitor doesn't
speak their language but goes in with a leaflet in the right
language you know, is that a face to face contact or what-
ever?' (CHC 06)
A nationally agreed protocol for informing carriers with
clear expectations of what information needs to be com-
municated to parents and practitioner roles, more
detailed than current guidance and similar for both con-
ditions, was suggested.
'Well, it's about clear expectations. About making sure that
there is clear linkage of what you do next. I think if you are
going into a family to give a result, it is not just good enough
to give a result and to give a leaflet. You must provide the
next level of intervention. And that next level in interven-
tion is about listening, and then signposting and very
clearly where you go next. And it isn't just about saying 'go
to your GP and they might refer you to clinical genetics'
because some GPs may not. So I think that needs to be
really erm...agreed before we sort this out. What is the kind
of things if people want further support? The other thingBMC Health Services Research 2007, 7:203 http://www.biomedcentral.com/1472-6963/7/203
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that needs to be clear, so that the Health Visitors are very
clear, is about we are not asking them to become genetics
experts and we are not asking them to become Sickle Cell
experts. ... we need to have some very clear role boundaries
of what is expected and that is agreed boundaries and part
of it is you may have a Health Visitor that is really inter-
ested and wants to do a lot more but is it appropriate?'
(CHC 05)
Explicit national policy regarding cascade screening (test-
ing of other family members), and whether and how to
report results detecting non-significant haemoglobin var-
iants would also be helpful. More practical proposals
included scripts on what parents should be told, espe-
cially when handling contentious scenarios such as non-
paternity; a leaflet for parents of SCD carriers (similar to
the current CF leaflet); simplification of current leaflets;
and review of when (timing) parents are told what the
bloodspot test is for.
As part of the call for continuity across both conditions,
integration of the two programmes was presented as
imperative to ensure consistency in practice (and argua-
bly, equity).
'The other stuff that we really, really need to do is to not to
do something totally different for CF and for Sickle because
we do an awful lot of going down different pathways and I
don't think that makes any sense...the integration of the
two programmes is just so important because it's really
hopeless if they don't erm...because you get these mixed
messages and you know you get it all being very special and
very different. I mean it's one of the issues I think all chil-
dren with chronic disease or carriers, they've got more in
common through being children than they have in having
a disease erm...and it seems to me we shouldn't be taking
people into different pathways simply because they've got
one type of disease.' (CHC 06)
Respondents felt that giving results should be 'normal-
ised' and incorporated into usual health care practice.
Where possible, lessons could be learnt from other screen-
ing programmes where results may be equally worrying.
Increased public awareness of the conditions and screen-
ing programmes was also mentioned as a way of allaying
parental concerns about carrier status.
'I think the biggest problem for the counsellors is getting
across to the parents that carrier status isn't a disease and I
think if we could raise the public's understanding of what
Sickle Cell was, I think that would help them enormously
because [otherwise]they've got to start from zero haven't
they really. And bring parents up because it can come out
of the blue can't it, they don't even know anything about it
and then you're telling them that there's something wrong
with their perfect baby.' (CHC 08)
Although confident that this task was within a non-spe-
cialist remit, participants noted concerns about practi-
tioner competence. In particular, General Practitioners'
(family physicians) limited knowledge about the implica-
tions of carrier status was perceived as concerning and
needed to be addressed.
Creation of a new post for a designated health profes-
sional within a specific locality, described as a 'newborn
bloodspot practitioner', to take responsibility for new-
born screening carrier results for all conditions was pro-
posed. This was seen as a practical way forward to
facilitate continuity in liaison with laboratories and other
stakeholders, and maintenance of professional compe-
tence in result giving.
The pressing need for research evidence to inform current
practice was emphasised. Participants wanted to know the
cost-effectiveness of various models and parental prefer-
ence for delivery format and information content.
Discussion
Recent US reports on CF newborn screening conclude that
policymakers must consider the need for genetic counsel-
ling services and ensure adequate resources to support
information giving prior to introducing newborn screen-
ing programmes [15,16]. European experience echoes this
call for clearly defined referral pathways to support maxi-
mum gain and minimise negative outcomes [17].
Research with parents following newborn screening sup-
ports disclosure of carrier status [18] and preference for
being informed by a familiar, non-specialist, health pro-
fessional [19]. Prior warning to expect the result [8] and
the need for concise information about newborn screen-
ing to be given during the antenatal period [20,21] are fur-
ther parental needs. In a retrospective study of parental
attitudes following carrier identification, no long-term
adverse outcomes were noted in the majority of families
[22]. However, the cost-effectiveness of face to face con-
sultation has been questioned [23] and rigorous evidence
on methods for communicating carrier results remains
lacking.
Our data on proposed models for imparting newborn car-
rier results across England suggest marked diversity, both
within and between regions, and within and between con-
ditions. Although influenced by national policy, other fac-
tors have shaped practice leading to pragmatic rather than
ideal choices. Despite overwhelming support for a similar
process for both conditions, only one region was imple-
menting a similar model for both conditions and varianceBMC Health Services Research 2007, 7:203 http://www.biomedcentral.com/1472-6963/7/203
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of methods was particularly noticeable for SCD carriers.
This creates concerns about equitable service provision.
Policy and accompanying funding may not address the
full implications of introducing new newborn screening
programmes in relation to giving carrier results and deal-
ing with parental information needs. As funding has sup-
ported only the front end costs of the process, such as
laboratory tests, health communities have had to find
additional resources within existing budgets, which may
result in less than ideal models for giving results.
Though modest in scale, these interviews with stakehold-
ers tasked with coordinating the implementation of new-
born screening programmes are likely to have covered the
full range of current models for giving carrier results in
England. Our respondents' views may not have embraced
perspectives beyond their own roles, for example those
from antenatal screening or primary care, though, this
would be unlikely to change the key messages and issues
for debate raised here.
Conclusion
Universal newborn screening for SCD and CF heralds a
new era for genetic screening in England [24]. While early
diagnosis of children affected by these disorders is the
aim, screening of populations will increasingly require
provision of information for those identified as gene car-
riers (and their families) with consequent challenges for
appropriate service models and workforce planning and
training.
Findings from this study raise important policy and prac-
tice issues for professionals with strategic and operational
responsibility for implementing newborn screening. For
example, the costly process of reporting in person, espe-
cially in terms of numbers of SCD carriers; challenges of
maintaining non-specialist informant competence given
small number of carriers per condition per year (while car-
rier numbers will be far greater for SCD relative to CF,
when translated to a primary care practice level, carriers of
either condition will still be a rare occurrence within a GP
or HV caseload); the need for more detailed national pro-
tocols; and equity and clinical governance concerns.
Our description of current practice may encourage shared
learning as newborn screening is rolled out, as well as a
context to stimulate evaluation and research about meth-
ods for imparting carrier results. Immediate priorities are
for practical support for implementation such as good
information leaflets, national protocols for information
giving, and additional resources to support carrier result
communication. Evidence for best practice when impart-
ing results will emerge over time as practice models evolve
and adjust.
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